Please login to the form below

Not currently logged in
Email:
Password:

cost and value

This page shows the latest cost and value news and features for those working in and with pharma, biotech and healthcare.

NICE: We're the institute of 'yes'

NICE: We're the institute of 'yes'

But Meindert Boysen told a London meeting conversations between the cost-effectiveness watchdog and the industry about value need to be conducted in a more open manner. ... all. Our job is to make sure we buy value. And if that value is increasing, then

Latest news

  • Amgen signs real world study and mobile data partnership Amgen signs real world study and mobile data partnership

    At the same time, we hope this research results in new tools and technology that support our provider partners who are on the journey to population health and value-based care.”. ... Joshua Ofman, Amgen's senior vice president of global value, access

  • IMS Health and Quintiles complete merger IMS Health and Quintiles complete merger

    The new offering - renamed QuintilesIMS - becomes the world's largest pharma services provider, with a market value of almost $18bn and around 50, 000 employees. ... QuintilesIMS said it would make cost, value and patient outcomes a top priority, and

  • Clinton takes aim at pharma pricing once again Clinton takes aim at pharma pricing once again

    scrutiny of the trajectory of price increases, the cost of production and the relative value to patients. ... drug costs, and ensuring drug companies invest in research and innovation rather than marketing.

  • IMS Health to merge with Quintiles IMS Health to merge with Quintiles

    The deal is expected to close in the second half of 2016, and the combined company - to be known as Quintiles IMS Holdings - will have a market value of almost $18bn, ... It also hopes to address universal healthcare issues of cost, value and patient

  • Paywatch and the market access waters Paywatch and the market access waters

    The episode once again shone a light on companies' pricing and reimbursement strategies and the whole argument around 'cost versus value'. ... In addition, conducting early rough assessments of likely cost-effectiveness as an iterative input to the

More from news
Approximately 1 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    The systems we have -. from the ICER Value Assessment Framework to the ASCO Value Framework - are often at odds with each other, and none of them wholly addresses all the attributes ... However, even if we do manage to fairly establish the value (and

  • Seismic shifts: Hepatitis C and payers Seismic shifts: Hepatitis C and payers

    But are we, as an industry, doing enough to support politicians, payers and the public in understanding both the value behind the acquisition cost and how medicines can be afforded when ... IMS Health market data shows that in the next 5 years 40% of

  • Determining value to withstand all tests Determining value to withstand all tests

    It's no longer enough for us to be ready to respond to value and pricing questions, we need to proactively communicate, engage and educate, and not just with decision makers. ... Ensuring a truly cross-functional approach to the creation of a value

  • Define the patient burden in rare diseases Define the patient burden in rare diseases

    For some, the value is purely objective and is a trade-off of the clinical benefit versus cost. ... work. For patients and their families, terms like 'value' and 'cost of a successful treatment' are at once objective and subjective.

  • UK market access: The importance of a local value story UK market access: The importance of a local value story

    CCGs will need to be convinced that a new drug brings value and is at a cost that can meet their budgetary needs. ... And to get more patients having more access to your products, you need to demonstrate value throughout the lifecycle, and work with

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Biosimilars - the Brexit of the pharmaceutical industry?

    of the  British Generic Manufacturers Association (BGMA).Biosimilars are undoubtedly a hot topic for providers of branded biologic medicines, biosimilar suppliers themselves, and the payers, healthcare professionals and patients involved in

  • The Heart of the Matter 7: Reality Dawns

    The drivers, benefits and value of RWE are now unquestionable. From a regulatory perspective, the Food and Drug Administration (FDA) has been requesting more post authorisation studies to monitor what happens ... It's all about making the right

  • Customer Service Representatives

    lower cost base. ... How can pharma bridge the gap, and provide value to patients and lower the cost of promotion?

  • ASCO 2015: What you missed in Chicago

    challenge Opdivo will depend on how the European markets provide access to it, as well as how issues of cost versus value of the treatment are addressed. ... Questions around cost and value still need to be urgently addressed by the medical community if

  • How can pharma engage with Accountable Care Systems?

    How can pharma engage with Accountable Care Systems? Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain how pharma can add value across care pathways. ... As a result, cost-based value propositions that guarantee outcomes and work to achieve

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics